Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 445

1.

Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.

Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D.

J Clin Oncol. 2004 May 1;22(9):1564-71. Epub 2004 Mar 29.

PMID:
15051756
[PubMed - indexed for MEDLINE]
Free Article
2.

Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer.

Arango D, Laiho P, Kokko A, Alhopuro P, Sammalkorpi H, Salovaara R, Nicorici D, Hautaniemi S, Alazzouzi H, Mecklin JP, Järvinen H, Hemminki A, Astola J, Schwartz S Jr, Aaltonen LA.

Gastroenterology. 2005 Sep;129(3):874-84.

PMID:
16143127
[PubMed - indexed for MEDLINE]
3.

A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients.

Bandrés E, Malumbres R, Cubedo E, Honorato B, Zarate R, Labarga A, Gabisu U, Sola JJ, García-Foncillas J.

Oncol Rep. 2007 May;17(5):1089-94.

PMID:
17390049
[PubMed - indexed for MEDLINE]
4.

Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.

Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C.

Oncology. 2006;70(5):366-77. Epub 2006 Dec 15.

PMID:
17179731
[PubMed - indexed for MEDLINE]
5.

Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.

Iinuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, Matsuda K, Fukushima R, Okinaga K, Sasako M, Mori M.

J Clin Oncol. 2011 Apr 20;29(12):1547-55. doi: 10.1200/JCO.2010.30.5151. Epub 2011 Mar 21.

PMID:
21422427
[PubMed - indexed for MEDLINE]
Free Article
6.

Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.

Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N, Wieand HS.

J Clin Oncol. 2003 Jan 15;21(2):241-50.

PMID:
12525515
[PubMed - indexed for MEDLINE]
Free Article
7.

Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.

Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O'Connell MJ, Furth AF, Sargent DJ, Murphy LM, Hill E, Riehle DL, Meyers CH, Witzig TE; North Central Cancer Treatment Group.

J Clin Oncol. 2004 May 1;22(9):1572-82.

PMID:
15117979
[PubMed - indexed for MEDLINE]
Free Article
8.

Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.

van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de Jong S, Kleibeuker JH, Koornstra JJ.

J Clin Oncol. 2006 Nov 1;24(31):4998-5004.

PMID:
17075118
[PubMed - indexed for MEDLINE]
Free Article
9.

Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery.

Galizia G, Ferraraccio F, Lieto E, Orditura M, Castellano P, Imperatore V, Romano C, Vollaro M, Agostini B, Pignatelli C, De Vita F.

Dis Colon Rectum. 2004 Nov;47(11):1904-14.

PMID:
15622584
[PubMed - indexed for MEDLINE]
10.

Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.

Specht K, Harbeck N, Smida J, Annecke K, Reich U, Naehrig J, Langer R, Mages J, Busch R, Kruse E, Klein-Hitpass L, Schmitt M, Kiechle M, Hoefler H.

Breast Cancer Res Treat. 2009 Nov;118(1):45-56. doi: 10.1007/s10549-008-0207-y. Epub 2008 Oct 17.

PMID:
18925433
[PubMed - indexed for MEDLINE]
11.

Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.

Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI.

Clin Cancer Res. 2005 Mar 15;11(6):2149-55.

PMID:
15788660
[PubMed - indexed for MEDLINE]
Free Article
12.

Caspase-3 activity, response to chemotherapy and clinical outcome in patients with colon cancer.

de Oca J, Azuara D, Sanchez-Santos R, Navarro M, Capella G, Moreno V, Sola A, Hotter G, Biondo S, Osorio A, Martí-Ragué J, Rafecas A.

Int J Colorectal Dis. 2008 Jan;23(1):21-7. Epub 2007 Sep 4.

PMID:
17805550
[PubMed - indexed for MEDLINE]
13.

Prognostic significance of CEA and CA 19-9 in colorectal cancer in Kuwait.

Behbehani AI, Al-Sayer H, Farghaly M, Kanawati N, Mathew A, al-Bader A, Van Dalen A.

Int J Biol Markers. 2000 Jan-Mar;15(1):51-5.

PMID:
10763141
[PubMed - indexed for MEDLINE]
14.

Gene expression signature predicts recurrence in lung adenocarcinoma.

Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, Fong KM.

Clin Cancer Res. 2007 May 15;13(10):2946-54.

PMID:
17504995
[PubMed - indexed for MEDLINE]
Free Article
15.

Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma.

Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Ghosh N, Trivedi TI.

Dis Colon Rectum. 2001 Apr;44(4):523-33.

PMID:
11330579
[PubMed - indexed for MEDLINE]
16.

Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, Jones J, Rockette H.

J Clin Oncol. 1999 May;17(5):1349-55.

PMID:
10334518
[PubMed - indexed for MEDLINE]
Free Article
17.

Tumor ploidy as a risk factor for disease recurrence and short survival in surgically treated Dukes' B2 colon cancer patients.

Nori D, Merimsky O, Saw D, Cortes E, Chen E, Chassin J.

Tumour Biol. 1996;17(2):75-80.

PMID:
8658016
[PubMed - indexed for MEDLINE]
18.

[Gene expression profiling in colon cancer].

Barrier A, Boelle PY, Lemoine A, Flahault A, Dudoit S, Huguier M.

Bull Acad Natl Med. 2007 Jun;191(6):1091-101; discussion 1102-3. French.

PMID:
18402166
[PubMed - indexed for MEDLINE]
19.

Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.

Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D, Luo JH.

Lancet Oncol. 2013 Dec;14(13):1295-306. doi: 10.1016/S1470-2045(13)70491-1. Epub 2013 Nov 13. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.

PMID:
24239208
[PubMed - indexed for MEDLINE]
20.

Classification of Dukes' B and C colorectal cancers using expression arrays.

Frederiksen CM, Knudsen S, Laurberg S, Ørntoft TF.

J Cancer Res Clin Oncol. 2003 May;129(5):263-71. Epub 2003 May 15.

PMID:
12750996
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk